Janux Therapeutics Inc
JANX23.339USD
-0.221-0.94%
Market hours （ET）Quotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM
More Details of Janux Therapeutics Inc Company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Company Info
Ticker SymbolJANX
Company nameJanux Therapeutics Inc
IPO dateJun 11, 2021
CEODr. David Campbell, Ph.D.
Number of employees74
Security typeOrdinary Share
Fiscal year-endJun 11
Address10955 Vista Sorrento Parkway
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92130
Phone18587514493
Websitehttps://www.januxrx.com/
Ticker SymbolJANX
IPO dateJun 11, 2021
CEODr. David Campbell, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
3.75K
--
Dr. Thomas Diraimondo, Ph.D.
Dr. Thomas Diraimondo, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Dr. David Campbell, Ph.D.
Dr. David Campbell, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Ms. Alana B. Mcnulty
Ms. Alana B. Mcnulty
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 26
Updated: Sat, Jul 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
18.92%
Fidelity Management & Research Company LLC
14.52%
Janus Henderson Investors
7.77%
Adage Capital Management, L.P.
6.18%
Paradigm BioCapital Advisors LP
5.63%
Other
46.99%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
18.92%
Fidelity Management & Research Company LLC
14.52%
Janus Henderson Investors
7.77%
Adage Capital Management, L.P.
6.18%
Paradigm BioCapital Advisors LP
5.63%
Other
46.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.46%
Hedge Fund
26.71%
Investment Advisor/Hedge Fund
24.89%
Venture Capital
21.78%
Corporation
5.07%
Private Equity
2.92%
Research Firm
2.37%
Individual Investor
1.76%
Pension Fund
0.86%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
406
71.41M
120.67%
-4.79M
2025Q1
413
73.50M
124.27%
-3.92M
2024Q4
403
71.29M
120.67%
+11.65M
2024Q3
335
56.66M
107.54%
-2.86M
2024Q2
298
57.26M
111.36%
+52.19K
2024Q1
242
56.34M
109.98%
+6.39M
2023Q4
179
48.33M
104.72%
-1.60M
2023Q3
169
48.51M
108.17%
+3.13M
2023Q2
166
43.90M
105.07%
-4.39M
2023Q1
159
44.18M
105.76%
-1.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
11.19M
18.92%
+3.75K
+0.03%
Jun 11, 2025
Fidelity Management & Research Company LLC
8.59M
14.52%
+28.68K
+0.33%
Mar 31, 2025
Janus Henderson Investors
4.60M
7.77%
+1.04M
+29.07%
Mar 31, 2025
Adage Capital Management, L.P.
3.65M
6.18%
+592.82K
+19.36%
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.33M
5.63%
-186.08K
-5.29%
Mar 31, 2025
Bregua Corp
3.00M
5.07%
-830.27K
-21.68%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.52M
4.25%
+116.37K
+4.85%
Mar 31, 2025
The Vanguard Group, Inc.
2.27M
3.84%
+142.33K
+6.69%
Mar 31, 2025
Cormorant Asset Management, LP
2.00M
3.38%
-100.00K
-4.76%
Mar 31, 2025
Logos Global Management LP
1.65M
2.79%
+400.00K
+32.00%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.63%
Tema Oncology ETF
1.73%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
SPDR S&P Biotech ETF
0.27%
Zacks Small/Mid Cap ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Invesco Nasdaq Biotechnology ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
iShares Biotechnology ETF
0.12%
T Rowe Price Small-Mid Cap ETF
0.07%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.63%
Tema Oncology ETF
Proportion1.73%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.81%
SPDR S&P Biotech ETF
Proportion0.27%
Zacks Small/Mid Cap ETF
Proportion0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
Invesco Nasdaq Biotechnology ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
iShares Biotechnology ETF
Proportion0.12%
T Rowe Price Small-Mid Cap ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
